Alethia Young
Chief Financial Officer

Alethia Young is Chief Financial Officer at Bicycle Therapeutics.

Alethia has more than 20 years of experience in the healthcare and biotech industry. Previously, Alethia was Chief Financial Officer at Graphite Bio, and prior to that, she served as senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. Before joining Cantor Fitzgerald in 2018, Ms. Young held senior biotech analyst positions at Credit Suisse and Deutsche Bank. Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions.

Alethia has a B.A. in Economics and Spanish from Duke University.